trending Market Intelligence /marketintelligence/en/news-insights/trending/-vOBNpf2Dq-jeyIbwPNg6w2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Targovax grants IOVaxis option to license, develop 2 vaccines in certain regions

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Targovax grants IOVaxis option to license, develop 2 vaccines in certain regions

Targovax ASA agreed to grant IOVaxis Therapeutics an exclusive option to develop and license certain vaccines in China, Hong Kong, Macau and Singapore.

IOVaxis, a spinoff from ImmuOn Therapeutics, has the option to develop and license the TG01 and TG02 mutant RAS neoantigen vaccines.

TG01 and TG02 induce specific T-cell responses against RAS mutations in the tumor cells that can potentially kill cell lines and isolated tumor cells with the mutation.

The option can be exercised into an exclusive license by the earlier of the first regulatory approval to start a clinical trial in the territory or one year from the effective date of the agreement.

IOVaxis will make a payment to Targovax for this exclusive option. The milestone payment for the exercise of the option to license TG01/02 is $3 million.

The companies will work together to prepare a development plan for the vaccines in the regions. Moreover, IOVaxis will be responsible for all local regulatory filings and will sponsor the clinical trials.

Targovax will be eligible to receive up to $100 million in total potential development and commercial milestone payments as well as royalties on net sales up to mid-double digits after IOVaxis exercises the option.

The companies have yet to finalize the full license agreement but have outlined key commercial and operational terms in the option agreement, Targovax noted in its Jan. 8 press release.

Locust Walk was the adviser to Targovax for the option agreement.